Seminars in Immunopathology最新文献_第5页

Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy. 靶向肿瘤重编程骨髓细胞:癌症免疫治疗的新战场。

IF 9 2区医学

Seminars in Immunopathology Pub Date : 2023-03-01 DOI: 10.1007/s00281-022-00965-1

Francesco De Sanctis, Annalisa Adamo, Stefania Canè, Stefano Ugel

{"title":"Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy.","authors":"Francesco De Sanctis, Annalisa Adamo, Stefania Canè, Stefano Ugel","doi":"10.1007/s00281-022-00965-1","DOIUrl":"https://doi.org/10.1007/s00281-022-00965-1","url":null,"abstract":"Tumour microenvironment is a complex ecosystem in which myeloid cells are the most abundant immune elements. This cell compartment is composed by different cell types, including neutrophils, macrophages, dendritic cells, and monocytes but also unexpected cell populations with immunosuppressive and pro-tumour roles. Indeed, the release of tumour-derived factors influences physiological haematopoiesis producing unconventional cells with immunosuppressive and tolerogenic functions such as myeloid-derived suppressor cells. These pro-tumour myeloid cell populations not only support immune escape directly but also assist tumour invasion trough non-immunological activities. It is therefore not surprising that these cell subsets considerably impact in tumour progression and cancer therapy resistance, including immunotherapy, and are being investigated as potential targets for developing a new era of cancer therapy. In this review, we discuss emerging strategies able to modulate the functional activity of these tumour-supporting myeloid cells subverting their accumulation, recruitment, survival, and functions. These innovative approaches will help develop innovative, or improve existing, cancer treatments.","PeriodicalId":21704,"journal":{"name":"Seminars in Immunopathology","volume":"45 2","pages":"163-186"},"PeriodicalIF":9.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9677008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 16. 合成长肽联合化疗或PD-1阻滞剂治疗16型人乳头瘤病毒引起的癌症。

IF 9 2区医学

Seminars in Immunopathology Pub Date : 2023-03-01 DOI: 10.1007/s00281-023-00986-4

Cornelis J M Melief, Esmé van der Gracht, Anna-Sophia Wiekmeijer

{"title":"Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 16.","authors":"Cornelis J M Melief, Esmé van der Gracht, Anna-Sophia Wiekmeijer","doi":"10.1007/s00281-023-00986-4","DOIUrl":"https://doi.org/10.1007/s00281-023-00986-4","url":null,"abstract":"Therapeutic vaccination of premalignant conditions and of different stages of cancer can be accomplished with several platforms including DNA vaccines, RNA vaccines, synthetic long peptides (SLP), and recombinant viruses. We successfully used a therapeutic vaccine composed of SLP covering the complete sequence of the two oncogenic proteins E6 and E7 of human papillomavirus type 16 (HPV16) as monotherapy in patients with premalignant disease. However, combination treatment might be required in patients with (advanced) cancer because of the hostile cancer microenvironment for T cells in established HPV16+ cancer, often associated with systemic immunosuppression. In patients with late-stage recurrent or metastatic HPV16+ cancers, we have therefore combined treatment with the SLP vaccine, called ISA101b, with either standard-of-care chemotherapy or with immune checkpoint inhibition with anti-PD-1 monoclonal antibody. A strong vaccine-induced interferon gamma-producing T cell response to HPV16 E6/E7 was associated with significantly better survival. In a second phase 1/2 study, patients with recurrent or metastatic HPV16+ oropharyngeal cancer were treated with the combination of ISA101b and anti-PD-1 (nivolumab). In this trial, the clinical overall response rate (ORR) in 22 patients was 36%, twice the ORR in the nivolumab registration trial for this category of patients, and 2/22 patients had a complete clinical response that is ongoing after 4 1/2 years. Other promising strategies for late-stage cancer recipients are the infusion of expanded tumor-infiltrating lymphocytes or the infusion of T cell receptor transduced T cells, both directed against HPV16.","PeriodicalId":21704,"journal":{"name":"Seminars in Immunopathology","volume":"45 2","pages":"273-277"},"PeriodicalIF":9.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9677051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Proteomics to study cancer immunity and improve treatment. 蛋白质组学研究癌症免疫和改善治疗。

IF 9 2区医学

Seminars in Immunopathology Pub Date : 2023-03-01 DOI: 10.1007/s00281-022-00980-2

Giulia Franciosa, Anders H Kverneland, Agnete W P Jensen, Marco Donia, Jesper V Olsen

{"title":"Proteomics to study cancer immunity and improve treatment.","authors":"Giulia Franciosa, Anders H Kverneland, Agnete W P Jensen, Marco Donia, Jesper V Olsen","doi":"10.1007/s00281-022-00980-2","DOIUrl":"https://doi.org/10.1007/s00281-022-00980-2","url":null,"abstract":"Cancer survival and progression depend on the ability of tumor cells to avoid immune recognition. Advances in the understanding of cancer immunity and tumor immune escape mechanisms enabled the development of immunotherapeutic approaches. In patients with otherwise incurable metastatic cancers, immunotherapy resulted in unprecedented response rates with the potential for durable complete responses. However, primary and acquired resistance mechanisms limit the efficacy of immunotherapy. Further therapeutic advances require a deeper understanding of the interplay between immune cells and tumors. Most high-throughput studies within the past decade focused on an omics characterization at DNA and RNA level. However, proteins are the molecular effectors of genomic information; therefore, the study of proteins provides deeper understanding of cellular functions. Recent advances in mass spectrometry (MS)-based proteomics at a system-wide scale may allow translational and clinical discoveries by enabling the analysis of understudied post-translational modifications, subcellular protein localization, cell signaling, and protein-protein interactions. In this review, we discuss the potential contribution of MS-based proteomics to preclinical and clinical research findings in the context of tumor immunity and cancer immunotherapies.","PeriodicalId":21704,"journal":{"name":"Seminars in Immunopathology","volume":"45 2","pages":"241-251"},"PeriodicalIF":9.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10051846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Local anesthetics and immunotherapy: a novel combination to fight cancer. 局部麻醉和免疫疗法:对抗癌症的新组合。

IF 9 2区医学

Seminars in Immunopathology Pub Date : 2023-03-01 DOI: 10.1007/s00281-022-00960-6

Lucillia Bezu, Oliver Kepp, Guido Kroemer

{"title":"Local anesthetics and immunotherapy: a novel combination to fight cancer.","authors":"Lucillia Bezu, Oliver Kepp, Guido Kroemer","doi":"10.1007/s00281-022-00960-6","DOIUrl":"https://doi.org/10.1007/s00281-022-00960-6","url":null,"abstract":"Intratumoral injection of oncolytic agents such as modified herpes simplex virus T-VEC or local administration of non-viral oncolytic therapies (such as radiofrequency, chemoembolization, cryoablation, or radiotherapy) can activate an anticancer immune response and hence trigger abscopal effects reducing secondary lesions. Preliminary data suggested that oncolytic treatments modulate tumor-infiltrating immune effectors and can be advantageously combined with the immune checkpoint inhibitors. Recent findings indicate that local anesthetics, which are usually used in the clinics to control surgical pain, also possess antineoplastic effects mimicking oncolytic treatments if they are injected into malignant lesions. Moreover, the association of local anesthetics with systemic immune checkpoint inhibition significantly improved overall survival in several preclinical tumor models. This may be explained by direct cytotoxic activity of local anesthetics and additional immune-related abscopal effects. We also summarize the molecular and cellular mechanisms by which the combination of local anesthetics and immunotherapy improves tumor control by the immune system.","PeriodicalId":21704,"journal":{"name":"Seminars in Immunopathology","volume":"45 2","pages":"265-272"},"PeriodicalIF":9.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9731444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

The role of macrophages in the tumor microenvironment and tumor metabolism. 巨噬细胞在肿瘤微环境和肿瘤代谢中的作用。

IF 9 2区医学

Seminars in Immunopathology Pub Date : 2023-03-01 DOI: 10.1007/s00281-023-00988-2

Pritam Sadhukhan, Tanguy Y Seiwert

引用次数: 4

CAF-immune cell crosstalk and its impact in immunotherapy. cafa -免疫细胞串扰及其在免疫治疗中的影响。

IF 9 2区医学

Seminars in Immunopathology Pub Date : 2023-03-01 DOI: 10.1007/s00281-022-00977-x

Ana Maia, Anna Schöllhorn, Juliane Schuhmacher, Cécile Gouttefangeas

{"title":"CAF-immune cell crosstalk and its impact in immunotherapy.","authors":"Ana Maia, Anna Schöllhorn, Juliane Schuhmacher, Cécile Gouttefangeas","doi":"10.1007/s00281-022-00977-x","DOIUrl":"https://doi.org/10.1007/s00281-022-00977-x","url":null,"abstract":"Tumour cells do not exist as isolated entities. Instead, they are surrounded by a variety of cells and extracellular matrix, which form the tumour microenvironment (TME). The interaction between cancer cells and their microenvironment is increasingly acknowledged as essential in dictating the outcome of the patients. The TME includes everything that surrounds tumour cells and is often highjacked by the latter to promote their growth, invasion, and immune escape. Immune cells and cancer-associated fibroblasts (CAFs) are essential components of the TME, and there is increasing evidence that their interaction constitutes a major player not only for tumour progression but also for therapy response.Recent work in the field of immuno-oncology resulted in the development of novel therapies that aim at activating immune cells against cancer cells to eliminate them. Despite their unprecedented success, the lack of response from a large portion of patients highlights the need for further progress and improvement. To achieve its ultimate goal, the interaction between cancer cells and the TME needs to be studied in-depth to allow the targeting of mechanisms that are involved in resistance or refractoriness to therapy. Moreover, predictive and prognostic biomarkers for patient stratification are still missing. In this review, we focus on and highlight the complexity of CAFs within the TME and how their interaction, particularly with immune cells, can contribute to treatment failure. We further discuss how this crosstalk can be further dissected and which strategies are currently used to target them.","PeriodicalId":21704,"journal":{"name":"Seminars in Immunopathology","volume":"45 2","pages":"203-214"},"PeriodicalIF":9.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10051836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Novel immunotherapeutic combinations moving forward: the modulation of the immunosuppressive microenvironment. 新的免疫治疗组合向前发展:免疫抑制微环境的调节。

IF 9 2区医学

Seminars in Immunopathology Pub Date : 2023-03-01 DOI: 10.1007/s00281-023-00991-7

Mads Hald Andersen

引用次数: 0

Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy. 单细胞技术揭示的非小细胞肺癌的免疫生物学:对免疫治疗患者生物标志物开发的影响

IF 9 2区医学

Seminars in Immunopathology Pub Date : 2023-01-01 DOI: 10.1007/s00281-022-00973-1

J Wlosik, S Fattori, P Rochigneux, A Goncalves, D Olive, A S Chretien

引用次数: 3

Learning cell identity in immunology, neuroscience, and cancer. 学习免疫学、神经科学和癌症中的细胞识别。

IF 9 2区医学

Seminars in Immunopathology Pub Date : 2023-01-01 DOI: 10.1007/s00281-022-00976-y

Stephanie Medina, Rebecca A Ihrie, Jonathan M Irish

{"title":"Learning cell identity in immunology, neuroscience, and cancer.","authors":"Stephanie Medina, Rebecca A Ihrie, Jonathan M Irish","doi":"10.1007/s00281-022-00976-y","DOIUrl":"https://doi.org/10.1007/s00281-022-00976-y","url":null,"abstract":"Suspension and imaging cytometry techniques that simultaneously measure hundreds of cellular features are powering a new era of cell biology and transforming our understanding of human tissues and tumors. However, a central challenge remains in learning the identities of unexpected or novel cell types. Cell identification rubrics that could assist trainees, whether human or machine, are not always rigorously defined, vary greatly by field, and differentially rely on cell intrinsic measurements, cell extrinsic tissue measurements, or external contextual information such as clinical outcomes. This challenge is especially acute in the context of tumors, where cells aberrantly express developmental programs that are normally time, location, or cell-type restricted. Well-established fields have contrasting practices for cell identity that have emerged from convention and convenience as much as design. For example, early immunology focused on identifying minimal sets of protein features that mark individual, functionally distinct cells. In neuroscience, features including morphology, development, and anatomical location were typical starting points for defining cell types. Both immunology and neuroscience now aim to link standardized measurements of protein or RNA to informative cell functions such as electrophysiology, connectivity, lineage potential, phospho-protein signaling, cell suppression, and tumor cell killing ability. The expansion of automated, machine-driven methods for learning cell identity has further created an urgent need for a harmonized framework for distinguishing cell identity across fields and technology platforms. Here, we compare practices in the fields of immunology and neuroscience, highlight concepts from each that might work well in the other, and propose ways to implement these ideas to study neural and immune cell interactions in brain tumors and associated model systems.","PeriodicalId":21704,"journal":{"name":"Seminars in Immunopathology","volume":"45 1","pages":"3-16"},"PeriodicalIF":9.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9455397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Towards multiomic analysis of oral mucosal pathologies. 对口腔黏膜病变进行多组学分析。

IF 7.9 2区医学

Seminars in Immunopathology Pub Date : 2023-01-01 Epub Date: 2023-02-15 DOI: 10.1007/s00281-022-00982-0

Jakob Einhaus, Xiaoyuan Han, Dorien Feyaerts, John Sunwoo, Brice Gaudilliere, Somayeh H Ahmad, Nima Aghaeepour, Karl Bruckman, David Ojcius, Christian M Schürch, Dyani K Gaudilliere

{"title":"Towards multiomic analysis of oral mucosal pathologies.","authors":"Jakob Einhaus, Xiaoyuan Han, Dorien Feyaerts, John Sunwoo, Brice Gaudilliere, Somayeh H Ahmad, Nima Aghaeepour, Karl Bruckman, David Ojcius, Christian M Schürch, Dyani K Gaudilliere","doi":"10.1007/s00281-022-00982-0","DOIUrl":"10.1007/s00281-022-00982-0","url":null,"abstract":"Oral mucosal pathologies comprise an array of diseases with worldwide prevalence and medical relevance. Affecting a confined space with crucial physiological and social functions, oral pathologies can be mutilating and drastically reduce quality of life. Despite their relevance, treatment for these diseases is often far from curative and remains vastly understudied. While multiple factors are involved in the pathogenesis of oral mucosal pathologies, the host's immune system plays a major role in the development, maintenance, and resolution of these diseases. Consequently, a precise understanding of immunological mechanisms implicated in oral mucosal pathologies is critical (1) to identify accurate, mechanistic biomarkers of clinical outcomes; (2) to develop targeted immunotherapeutic strategies; and (3) to individualize prevention and treatment approaches. Here, we review key elements of the immune system's role in oral mucosal pathologies that hold promise to overcome limitations in current diagnostic and therapeutic approaches. We emphasize recent and ongoing multiomic and single-cell approaches that enable an integrative view of these pathophysiological processes and thereby provide unifying and clinically relevant biological signatures.","PeriodicalId":21704,"journal":{"name":"Seminars in Immunopathology","volume":"45 1","pages":"111-123"},"PeriodicalIF":7.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9098633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0